|Articles|December 1, 2001

CMS expands coverage for verteporfin therapy

New York-The Centers for Medicare and Medicaid Services (CMS)-formerlythe Health Care Financing Administration-will begin reimbursing patientswho use verteporfin for injection (Visudyne) with occult choroidal neovascularization(CNV) lesions secondary to age-related macular degeneration (AMD).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Latest CME